



ARSEUS
Driving superior care

Press Release

Regulated information

DISCLOSURE OF RECEIVED NOTIFICATION

Waregem (Belgium) / Rotterdam (the Netherlands)¹, 4 April 2013 – Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Arseus NV announces that the number of shares held by Arseus NV has passed the disclosure threshold of 3% on 27 March 2013.

Based on the total of 31,278,514 (total number of voting rights) and the relevant notifications received by Arseus, the shareholder structure of Arseus on 27 March 2013 is as follows:

	Number of shares	% of effective voting rights
EnHold NV	8,166,908	26.11%
Alychlo NV / Coucke	3,528,080	11.28%
BNP Paribas Investment Partners SA	1,546,052	4.94%
Arseus NV (treasury shares)	960,296	3.07%
Public	17,077,178	54.60%
Total	31,278,514	100.00%

The original notification forms are available at www.arseus.com.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

For more information:

Veronique Lefel
Investor Relations Officer
+31 88 33 11 213 (Office)
+31 6 105 77 754 (Mobile)
veronique.lefel@arseus.com

¹ This press release was sent out by Arseus NV and Arseus BV.

Arseus profile

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in 29 countries in Europe, North America, South America, Asia, Australia and Africa. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.